A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving durvalumab in combination with tremelimumab.

Front Immunol · 2025 · PMC12605205 · PMID 41235246

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

AE reports showed an increasing trend over time, with proportions of 7.3% in 2020, 23.5% in 2023, and 68.5% in 2024.

also in 63,971 other papers

highly significantno p-value reported

After Bonferroni correction for multiple testing, these associations remained highly significant, confirming the robustness of the detected safety signals ( Figure 2C ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.